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Abstract
Left ventricular assist device (LVAD) therapy remains a vital therapeutic option for
patients with end-stage heart failure. Unfortunately, adverse events can occur and
progress to require consideration for device exchange once the failure of medical
management becomes evident, especially when heart transplantation is not
possible in a timely manner. The aim of this analysis is to describe the incidence
and outcomes of LVAD exchanges at our institution. Between April 2008 and May
2017, 397 patients underwent LVAD implantation, with 32 of those patients
subsequently receiving exchange upon the recommendation of our
multidisciplinary team due to refractory infection (n=12), device malfunction (n=5),
hemolysis (n=9) and pump thrombosis (n=6). The average time from index implant
to exchange was 580.6 days, with an average length of stay of 18.2 days. Survival
at 3 months was 84.4%, 75.0% at 1 year and median at 8.3 years after exchange.
The most common adverse events, occurring in less than 1/3 of the population,
included bleeding, infection and stroke. This study suggests that LVAD exchange
can be an effective and definitive mechanism for the treatment of otherwise
potential fatal pump complications in highly select patients.
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Introduction
Heart failure is the leading cause of hospitalizations annually, with recent
estimates of Americans 40 years or older facing a 20% lifetime risk, a prevalence
of over 9 million Americans by 2030. 1 A significant proportion of patients will
unfortunately go on to fail medical therapy, requiring the use of advanced
treatment strategies for end-stage heart failure. While many patients at this stage
can be successfully treated with transplantation, a large number have
comorbidities that prevent eligibility for the therapy, or have unacceptably
prolonged wait times, thereby making durable left ventricular assist device (LVAD)
support their most viable therapeutic option.2-3 However, serious complications
necessitating device exchange can include pump thrombosis, hemolysis and
infection, posing challenging management scenarios for those who remain
ineligible for transplantation after LVAD or have a prolonged wait time and
experience a complication while on mechanical support. 4
Risk factors for adverse events leading to exchange commonly include deviation
from standardized implant and immediate/long-term management techniques,
advanced age, immunosuppressed states such as diabetes, elevated blood
pressure and patient non-compliance.5-8 Methods to improve outcomes and
decrease adverse events include careful instruction on routine maintenance of the
driveline, accurate monitoring of anticoagulant and antiplatelet therapy and
aggressive antibiotic therapies when indicated (oral and parenteral), guided by
culture data in consultation with an infectious disease specialist.
Unfortunately, some patients still progress to consideration for LVAD exchange
once the failure of medical management becomes evident, especially when
transplantation is not possible in a timely manner. This analysis describes the
incidence and outcomes of LVAD exchange procedures at our institution.

Methods
A retrospective analysis of our institution’s LVAD database was performed. During
a 9-year period, 397 patients underwent LVAD implantation between April 2008
and May 2017, with 32 of those patients subsequently receiving LVAD exchange
between September 2009 and March 2017. Only initial pump exchange patients
were included in the reviewed cohort. The reasons for exchange included:
refractory infection, evidence of device malfunction, hemolysis and pump
thrombosis. Surgical approach varied based on device and indication for exchange
and included subcostal or full sternotomy approaches.
Descriptive analysis, Kaplan-Meier survival estimates and time to first event were
then calculated. Outcomes of interest included death, hemolysis, pump
thrombosis, stroke, right heart failure, bleeding and infection. The time between
initial implant and exchange, length of post-operative hospital stay, discharge
location and average time to follow-up after discharge were monitored to provide
an objective standard for post-operative patient management.The decision to
exchange the device was defined by the failure of medical therapy as determined
by an interdisciplinary team of cardiologists, infectious disease specialists and
surgeons. Specific criteria for exchange in cases of infection included refractory
The VAD Journal: https://doi.org/10.13023/vad.2019.05

Page 2 of 10

The VAD Journal: The journal of mechanical assisted circulation and heart failure

infection as guided by physical examination, laboratory, culture and imaging data
despite appropriate culture-guided antibiotic therapy. Ongoing laboratory and
pump parameters were used to define hemolysis and pump thrombosis according
to the accepted Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) definitions.3 Infection data, concomitant medications and
antibiotic history were collected to investigate the most common risk factors and
pathogens involved and any possible correlations with surgical outcomes.
The surgical approach focused on incision type – patients required sternotomy
when complete device extraction was necessary to address their reason for pump
exchange. In cases of infection, full sternotomy was only performed when infection
ascended beyond the pump pocket.

Results
Baseline demographics, surgical approach, reviewed models and patient status
can be found in Table 1.
Table 1. Baseline Characteristics (HMII - HeartMate, HVAD - Heartware
Ventricular Assist Device, BTT - Bridge to Transplantation, DT - Destination
Therapy)
Deciding Factor for Exchange
Infection (N =
12)

Other (N = 20)

Age : Average

44.5

52.8

Gender: Males

10

13

Caucasian

12

15

African American

0

5

BMI (kg/m2) : Average

32.8

31.2

HMII → HMII

9

17

HVAD → HVAD

1

2

HMII → HVAD

2

1

Subcostal

8

13

Sternotomy

4

7

BTT

6

7

DT

6

13

Demographics

Race

VAD Model Exchanges

Incision Type

Status
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Reason for exchange in the overall cohort included infection (n=12), hemolysis
(n=9), pump thrombosis (n=6) and pump malfunction (n=5) (Table 2). Pump
malfunction included driveline or internal wire fracture (n=2), pump migration (n=2)
and detachment of outflow graft (n=1). Of note, 71.4% of patients going on to
exchange were diagnosed and treated for infection during the evaluated timeline.
The most common infections included Staphylococcus (40%), Pseudomonas
(11.4%) and Enterococcus (8.6%); however, some patients had more than one
isolated bacteria responsible for their infections (Table 3). Appropriate antibiotics
were guided by culture data, with a median treatment course of 184 days before
exchange. The average time from index implant to exchange was 580.6 days, with
an average length of stay after exchange of 18.2 days.
Table 2. Deciding Factor for Exchange
Deciding Factor for
Exchange
Infection

12

Hemolysis

9

Pump
Thrombosis
Pump
Malfunction

6
5

Table 3. Organism Culture prior to Exchange (MSSA - Methicillin Sensitive
Aureus, CoNS - Coagulase Negative Staphylococcus)Staphylococcus
Aureus, MRSA - Methicillin Resistant Staphylococcus

Organism cultured prior to exchange
MSSA MRSA CoNS Pseudomonas Acinetobacter Aerococcus Stenotrophomonas Proteus
viridans
5
2
2
2
1
1
1
1
*4 patients with double infection at the time of exchange
Twenty-seven patients (77.1%) were discharged directly home following the
exchange, 5 (14.3%) to a long-term care skilled nursing facility or acute
rehabilitation unit and 5 died within 90 days. Causes of death included
intracerebral hemorrhage (2), respiratory failure (1), mycotic aneurysm (1) and
cardiac arrest (1). Survival at 3 months for the combined cohorts was 84.4%,
75.0% at 1 year and median 8.3 years after exchange. Survival post exchange for
the infection group was 92% and 83.% at 3 months and 1 year, respectively, while
survival “other” group was 80% and 70% at those same time intervals (Figure 1).
Adverse events experienced after initial exchange are included in Table 4. The
most common complications included stroke, recurrent infection and
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gastrointestinal (GI) bleed. Five patients eventually went on to cardiac
transplantation.

Figure 1. Kaplan Meier Curve of Survival for Infection vs. Other
The survival post exchange at 3 months is 92% for the infection group, and at 1
year is 83.%. Survival post exchange for the ‘other’ group at 3 months is 80%, and
at 1 year is 70%. With small sample sizes, p-values were not calculated. The
overall median survival was > 8.3 years
Median survival was calculated only within the reviewed time frame. There were
12 deaths after exchange with average survival time of at least 2.5 years. Within
the 12 patients exchanged due to infection, there were 3 mortalities with average
time to death at 1.1 years. One patient died after 52 days.
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Table 4. Post Exchange Adverse Events
Post Exchange Adverse Events (N=32)
Event

N

Average Time to
Event (years)

Hemolysis

4

1.2

Right Heart Failure

2

1.6

Other Bleed
Gastrointestinal Bleeding

4

1.3

7

0.6

Stroke

12

0.6

Transient ischemic Attack

1

0.13

Ischemic

3

0.3

Intracranial Hemorrhage

8
13

0.7
0.6

Infection

Discussion
In an era of a growing advanced heart failure population, strategies other than the
often-limited option of cardiac transplantation must be considered. If LVAD
utilization increases with this mounting population, so do the potential for
downstream complications such as pump thrombosis, hemolysis, and infection.
Even if heart transplantation remains an option for these complex patients after a
LVAD complication, the appropriate organ may not become available in adequate
time, risking further deterioration and critical illness. Our data indicates these
patients can be safely exchanged with reasonable post-operative courses, short
post-operative length of stays and positive long-term outcomes, with rates of
survival in this analysis of re-operative patients being slightly lower than the
current rates of post-operative survival with continuous flow devices.3 To our
knowledge, this is the largest study of LVAD exchanges yet to be reported.
Notably, for the patients with infection, the risks associated with the exchange are
entirely acceptable in comparison to the risks associated with the near certain
progression of disseminated infection. Each patient’s historical factors, physical
characteristics, laboratory, culture and imaging data were used to determine the
diagnosis and extent of infection. The exchange was only undertaken after an
interdisciplinary team (representing cardiology, infectious disease, and surgery)
determined failure of medical therapy. Individual patient characteristics such as
adherence to medical recommendations, psychosocial factors, surgical history,
antibiotic history and extent of infection were carefully considered before
undertaking the task of an exchange. Furthermore, type of bacterial infection and
the ability for complete eradication by stringent washout before re-implantation of a
new device with subsequent long-term antibiotics was weighed against any
potential morbidity or mortality from the procedure, the ability to undergo a full
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sternotomy if necessary and a shared-decision making process with the
aforementioned factors in mind.
While the risk factors for exchange are not always clear, we attempt to adhere to
the instructions for use for the particular LVAD being implanted, inclusive of
anticoagulation and antiplatelet therapies, as well as the PREVENT
recommendations for peri-operative and long-term management of HeartMate II
patients. We pay close attention to the recommendations from the PREVENT
guidelines for intra-operative considerations, heparin bridging, and pump speeds >
9,000 RPMs. We also advise patients to change their driveline dressings using
sterile precautions daily in the early post-operative phase, not shower until fully
incorporated and change dressings when showering or at least twice weekly
thereafter. Our infectious disease team assesses patients preoperatively and
during the immediate post-operative period, and as needed should any infectious
issues arise. Additionally, many studies demonstrate elevated blood pressure with
an increased risk of adverse events, with the best examples coming from the
Heartware VAD populations.10,11 As doppler blood pressure most closely
approximates systolic blood pressure and mean arterial blood pressure,12 our
center’s practice is to aim for a goal of <90mm Hg.
While patient adherence is often an issue, modification and attention to the
specifics of medical management following LVAD implantation can have a
substantial impact on post-surgical complications and improved quality of life.6 Our
multidisciplinary team inclusive of surgical, medical, infectious disease,
hematology, supportive/palliative care, pharmacy, nursing and social work
colleagues continually re-educate patients on the importance of adherence to best
practices regarding blood pressure, anticoagulation and driveline management.
Based on our experience, we propose that LVAD exchanges only be performed
once such an interdisciplinary committee has convened and determined that a
device complication is indeed refractory to medical therapy. In preparation for
exchange, a risk mitigation plan to prevent need for re-exchange must be in place
to aid in long-term monitoring and support as part of the patient’s treatment plan as
a bridge to transplantation or destination therapy.

Study Limitations
Not all possible confounding variables were recorded or adjusted for in this study.
While confounding patient characteristics (compliance, psychosocial barriers and
financial limitations) were considered during the evaluation for exchange, it is
difficult to objectively quantify these risk factors as associated with long-term
outcomes after each exchange. This patient population also experienced careful
evaluation and counseling by Palliative/Supportive Care Medicine specialists to aid
in decision making and management of chronic pain, fatigue and distress. This
counsel may have resulted in the patient opting against device exchange as a
potential option, particularly if a full exchange was recommended – the exact
number of patients who opted against exchange in this situation is not available.
The limited size of this study along with the other stated limitations do not
necessarily allow these findings to be generalizable to an entire LVAD population.
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Finally, the retrospective nature of the study contributes to possible bias and
discrepancies in collecting and reviewing data.

Clinical Implications
The results of our study suggest that LVAD exchange can be an effective and
definitive mechanism for the treatment of otherwise potentially fatal pump
complications in highly select patients. Complex patients such as those analyzed
in our cohort can be safely exchanged with outcomes that improve both longevity
and quality of life. Patients reported ability to complete ADLs, return to work and
ambulate with more easily allowing further enjoyment of life. No specific,
formalized quality of life data was uniformly available in this retrospective review.
Risks associated with the exchange procedure are minimal in comparison to the
risks associated with the potential for disseminated infection or disease worsening
arising from ongoing pump malfunction. If patients are continually educated on the
care of their device and have a reliable support system in place, LVAD exchange
should be considered in cases where no other solutions are available in a timely
fashion.
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